Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationPaul B. Chapman, Grant A. McArthur, Jeffrey A. Sosman et al.|New England Journal of Medicine|2011Cited by 7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|The Lancet|2012Cited by 3k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, Paul B. Chapman et al.|The Lancet Oncology|2014Cited by 978
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Axel Hauschild et al.|The Lancet Oncology|2015Cited by 244
Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 casesB. Vergier, Jean‐Philippe Merlio, Martina Prochazkova‐Carlotti et al.|Modern Pathology|2010Cited by 140